|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Second Sight Medical Products |
|---|---|
| Information provided by: | Second Sight Medical Products |
| ClinicalTrials.gov Identifier: | NCT00279500 |
Purpose
The objective of this study is to evaluate the safety and efficacy of the retinal stimulation system by evaluating the data after chronic implantation.
| Condition | Intervention | Phase |
|---|---|---|
|
Retinitis Pigmentosa |
Device: Argus 16 Retinal Stimulation System |
Phase I Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Chronic Retinal Electrodes to Provide Electrical Stimulation of the Retina to Elicit Visual Percepts in Blind Subjects |
| Estimated Enrollment: | 8 |
| Study Start Date: | February 2002 |
| Estimated Study Completion Date: | December 2007 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| Doheny Eye Institute | |
| Los Angeles, California, United States, 90033 | |
| Principal Investigator: | Mark Humayun, MD PhD | Doheny Eye Institute |
More Information
| Study ID Numbers: | CP0002 |
| Study First Received: | January 17, 2006 |
| Last Updated: | January 8, 2007 |
| ClinicalTrials.gov Identifier: | NCT00279500 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Genetic Diseases, Inborn Eye Diseases Retinitis Pigmentosa Retinitis |
Retinal Degeneration Eye Diseases, Hereditary Retinal Diseases |